Search

Displaying results 4391 - 4400 of 8578 in total
  1. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

  2. Drug

    BacTRL-spike

    go.drugbank.com/drugs/DB15811
    Investigational

    The vaccine was developed by Symvivo Corporation. … As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.

  3. Drug

    Casdatifan

    go.drugbank.com/drugs/DB21701
    Investigational

    Casdatifan has a monoisotopic molecular weight of 439.09 Da. … Casdatifan is under investigation in clinical trial NCT07000149 (A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC)

  4. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  5. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  6. Drug

    5-amino-1,3,4-thiadiazole-2-thiol

    go.drugbank.com/drugs/DB12348
    Investigational

    ATT has been investigated in Pulmonary Tuberculosis.

  7. Drug

    Bucindolol

    go.drugbank.com/drugs/DB12752
    Investigational

    Bucindolol has been investigated in Heart Failure.

  8. Drug

    Ilaprazole

    go.drugbank.com/drugs/DB11964
    Investigational

    Ilaprazole has been investigated in Helicobacter Infections.

  9. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

  10. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]